4basebio PLC (AIM:4BB)
London · Delayed Price · Currency is GBP · Price in GBX 482.50
-22.50 (-4.46%)
Apr 15, 2026, 4:08 PM GMT
4basebio Market Cap
4basebio has a market cap or net worth of 78.16 million as of April 15, 2026. Its market cap has decreased by -47.61% in one year.
Market Cap
78.16M
Enterprise Value
67.48M
Revenue
1.78M
Ranking
n/a
PE Ratio
n/a
Stock Price
482.50
Market Cap Chart
Since February 17, 2021, 4basebio's market cap has increased from 41.57M to 78.16M, an increase of 88.02%. That is a compound annual growth rate of 13.02%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Apr 15, 2026 | 78.16M | -17.89% |
| Dec 31, 2025 | 95.19M | -38.57% |
| Dec 31, 2024 | 154.94M | 84.96% |
| Dec 29, 2023 | 83.77M | -4.21% |
| Dec 30, 2022 | 87.45M | 15.45% |
| Dec 31, 2021 | 75.75M | 82.22% |
| Feb 17, 2021 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Scancell Holdings | 129.72M |
| Bioventix | 95.35M |
| hVIVO | 59.19M |
| Ondine Biomedical | 58.45M |
| Hemogenyx Pharmaceuticals | 55.58M |
| Faron Pharmaceuticals Oy | 51.41M |
| Poolbeg Pharma | 31.73M |
| ImmuPharma | 29.42M |